SPDL1 and colorectal carcinoma: To further explore sPD-L1 as a potential biomarker to predict the outcome of immunotherapy in pMMR CRC, we included 40 patients treated with regorafenib combined with sintilimab, a PD-1 inhibitor (two plasma samples at C4 were not acquired).